FcRn — Drug Target

All drugs that target FcRn — marketed and clinical-stage. Includes 2 drug classes acting on this target.

Drug classes

Endoglycosidase [EPC] · Monoclonal antibody

Marketed (1)

• Efgartigimod · M. Peter Marinkovich · Endoglycosidase [EPC] · Immunology
  Efgartigimod alfa binds to FcRn, reducing circulating IgG, while hyaluronidase increases subcutaneous permeability.

Phase 3 pipeline (2)

• efgartigimod IV · argenx · Monoclonal antibody · Immunology
  Efgartigimod IV is a monoclonal antibody that targets and depletes neonatal Fc receptor (FcRn), thereby reducing the levels of immunoglobulin G (IgG) in the body.
• efgartigimod administration · Clinique Neuro-Outaouais · Monoclonal antibody · Autoimmune diseases
  Efgartigimod is a monoclonal antibody that targets and depletes neonatal Fc receptor (FcRn) to reduce immunoglobulin G (IgG) levels.

Phase 1 pipeline (1)

• ARGX-113 with rHuPH20 · argenx · Monoclonal antibody · Immunology
  Monoclonal antibody targeting the neonatal Fc receptor (FcRn)